Access and Safety-The FDA Drug Approval Conundrum

被引：1

作者：

Good, Chester B. ^{[1
]}

Peasah, Samuel K. ^{[2
]}

机构：

[1] Univ Pittsburgh, Insurance Serv Div, UPMC Hlth Plan, 600 Grant St,Univ Dr C, Pittsburgh, PA 15219 USA

[2] Univ Pittsburgh, Ctr Value Based Pharm Initiat, Insurance Serv Div, UPMC Hlth Plan, Pittsburgh, PA USA

来源：

JAMA NETWORK OPEN | 2024年 / 7卷 / 07期

关键词：

D O I：

10.1001/jamanetworkopen.2024.19823

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 8 条

[1]

[Anonymous], Approved Risk Evaluation and Mitigation Strategies (REMS)

[2]

[Anonymous], Highlights of prescribing information

[3]

Desai RJ, 2020, JAMA NETW OPEN, V3, DOI [10.1001/jamanetworkopen.2019.18962, 10.1001/jamanetworkopen.2019.10626]

[4] Removing the FDA's Boxed Hepatotoxicity Warning and Liver Function Testing Requirement for Ambrisentan [J].

Feldman, William B. ;

Mahesri, Mufaddal ;

Sarpatwari, Ameet ;

Huybrechts, Krista F. ;

Zhu, Yanmin ;

Hwang, Catherine S. ;

Lii, Joyce ;

Lee, Su Been ;

Sreedhara, Sushama Kattinakere ;

Toyserkani, Gita A. ;

Zhou, Esther H. ;

Zendel, Laura ;

Lacivita, Cynthia ;

Manzo, Claudia ;

Dal Pan, Gerald J. ;

Kesselheim, Aaron S. ;

Bykov, Katsiaryna .

JAMA NETWORK OPEN, 2024, 7 (07) :e2419873

[5]

Moran M, 2024, Psychiatric News, V59, DOI [10.1176/appi.pn.2024.01.1.42, 10.1176/appi.pn.2024.01.1.42, DOI 10.1176/APPI.PN.2024.01.1.42]

[6] Cerivastatin and reports of fatal rhabdomyolysis. [J].

Staffa, JA ;

Chang, J ;

Green, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (07) :539-540

[7]

US Food and Drug Administration, 2000, Center for Drug Evaluation and Research: application number 20-740/S008/S013

[8]

US Food and Drug Administration, 1997, Center for Drug Evaluation and Research: application number 020740

← 1 →